Estimation of National Economic Burden of Hypoglycaemia Among Type 2 Diabetes Mellitus Patients in Malaysia

Abstract

A897nostic approach remained cost-effective even triple of patients were diagnosed and treated for gestational diabetes mellitus. ADA 2011 diagnostic approach, however, was no longer cost-effective when long-term maternal and neonatal outcomes were not considered. ConClusions: Screening at 24-28 weeks' gestational age under the ADA 2011 guidelines with the 2h OGTT is expensive but cost effective in improving long-term maternal and neonatal outcomes.

<p>Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia</p>

“…27 The cost of managing a hypoglycemia event was taken from a local study carried out at Universiti Kebangsaan Malaysia Medical Centre. 28 The management cost of hypoglycemia increased with each level of severity. It is estimated that the cost of managing a severe hypoglycemia case was MYR 8250.…”

“…It is estimated that the cost of managing a severe hypoglycemia case was MYR 8250. 28 The acquisition costs (obtained from a Malaysia's public hospital 2015-year purchase price) for the insulins were calculated from prices according to pack size. The price for NPH insulin (Novapen ® ) is RM 5.13 (US$ 1.22) per cartridge, insulin Glargine (Lantus ® ) is RM 34.81 (US$ 8.27) per cartridge and insulin Detemir (Levemir FlexTouch ® ) is RM 36.58 (US$ 8.70) per cartridge.…”